2652.HK
Biokin does biopharma

Pharmaceutical manufacturer CF PharmTech Inc. (2652.HK) on Friday launched its Hong Kong IPO, seeking to raise about HK$601 million ($77 million) by selling 41.2 million shares for HK$14.75 apiece. The subscription period for shares will close on Oct. 2, with trading slated to begin on Oct. 8.

The company plans to use 40% of the IPO proceeds for R&D of its inhaled product candidates and for ongoing clinical initiatives. About 20% will go to preclinical programs for multiple pipeline candidates and technological platforms. Another 30% is earmarked for purchasing equipment and expanding and upgrading the company’s production management systems.

CF PharmTech reported revenue of nearly 610 million yuan last year, up 9% year-on-year. Its profit for the year totaled 21.09 million yuan, down 33.5%. Its first-quarter revenue this year reached 136 million yuan, down 2.7% year-over-year, while its profit for the period more than doubled to 12.82 million yuan.

By Lau Chi Hang

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Zepp makes wearable products

Zepp hits its stride with return to revenue growth

The maker of low-end wearable devices reported its revenue rose 78.5% in the third quarter, but forecast the rate would ease to about 40% in the current quarter Key Takeaways:…
Man Wah subsidiary Remacro NEEQ listing

Man Wah sets spin-off in motion for its sofa tech unit

The Chinese furniture giant is preparing to list its components subsidiary Remacro to raise the technology unit’s profile and open an independent funding channel Key Takeaways: After listing on China’s…